Leo Pharma

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ESTE, PR, TMBR

Retrieved on: 
Sunday, August 27, 2023
Permian, Petroleum & Resources Corporation, Lumber, Fraud, Leo Pharma, NYSE, Advertising, Sale, Security (finance)

If you are an Earthstone shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Earthstone shareholder, click here to learn more about your rights and options .
  • If you are a Permian shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL

Retrieved on: 
Sunday, August 27, 2023
Permian, PR, Leo Pharma, Telephone, Sale, Eurasian Natural Resources Corporation, Advertising, CELL, Hewlett, Bruker, Online shopping

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of PR and Earthstone Energy, Inc.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of PR and Earthstone Energy, Inc.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of ESTE and Permian Resources Corporation.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CELL to Bruker Corporation for $1.00 per share in cash for each share of CELL common stock owned.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

LEO Pharma announces changes to its Global Leadership Team

Retrieved on: 
Monday, August 28, 2023
General Health, Pharmaceutical, Health, Other Health, Global leadership, Corporate Affairs, Leo Pharma, Culture, MBA, McKinsey & Company, Novartis, INSEAD, LEO, ESSEC, ESG, Family, Skin, Management, Pharmaceutical industry

Today, LEO Pharma announced the appointment of Nathalie Daste as new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023.

Key Points: 
  • Today, LEO Pharma announced the appointment of Nathalie Daste as new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023.
  • In her new role, Nathalie Daste will head LEO Pharma’s Global People function as well as Corporate Affairs, including sustainability and ESG.
  • Her vast experience from global life-science makes her a catch for LEO Pharma as we have been looking for a successor to Dennis Schmidt Pedersen.
  • With her joining the Global Leadership team, we can ensure these insights are brought into strategy.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR

Retrieved on: 
Tuesday, August 22, 2023
Permian, Leo Pharma, Computer Task Group, Sale, Petroleum & Resources Corporation, Advertising, Computation, Lumber, Fraud, NYSE, Security (finance)

If you are a Computer Task shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Computer Task shareholder, click here to learn more about your rights and options .
  • If you are an Earthstone shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CTG, TMBR, HEP, CEQP

Retrieved on: 
Monday, August 21, 2023
Transfer, Energy, Leo Pharma, Computer Task Group, HEP, Sinclair (surname), Empire, Energy Transfer Partners, Sale, CTG, Monteverde, HF Sinclair, NYSE, Security (finance)

Under the terms of the agreement, CTG shareholders will receive $10.50 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, CTG shareholders will receive $10.50 in cash per share they own.
  • It is free and there is no cost or obligation to you.
  • Crestwood Equity Partners LP (NYSE: CEQP ), relating to its proposed sale to Energy Transfer LP.
  • Under the terms of the agreement, CEQP shareholders will receive 2.07 shares of Energy Transfer per share they own.

Timber Pharmaceuticals to be Acquired by LEO Pharma

Retrieved on: 
Monday, August 21, 2023
LLP, CVR, Covington & Burling, Leo Pharma, Calendar, Securities and Exchange Commission (Nigeria), Ichthyosis, Patient, CVR Partners, LEO, Security (finance), FDA, Black–Scholes model, NYSE, Skin, Pharmaceutical industry, Lumber

As part of the transaction, LEO Pharma has agreed to provide Timber with a bridge loan of up to $3.0 million, subject to certain conditions.

Key Points: 
  • As part of the transaction, LEO Pharma has agreed to provide Timber with a bridge loan of up to $3.0 million, subject to certain conditions.
  • The payments of the CVRs are subject to certain deductions relating to the repayment of 50% of the bridge loan provided by LEO Pharma to Timber in connection with the merger.
  • LEO Pharma is a leader in global dermatology with a mission that matches our own - a relentless pursuit to help patients suffering from skin diseases.
  • Covington & Burling LLP is serving as legal counsel to LEO Pharma.

TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, August 21, 2023
Class Action Lawsuit, Professional Services, Legal, Fraud, Leo Pharma, NYSE, Advertising, Sale, Lumber

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Timber Pharmaceuticals, Inc. (NYSE: TMBR) to LEO Pharma A/S is fair to Timber shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Timber Pharmaceuticals, Inc. (NYSE: TMBR) to LEO Pharma A/S is fair to Timber shareholders.
  • On behalf of Timber shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals

Retrieved on: 
Monday, August 21, 2023
Health, Pharmaceutical, Skin, Leo Pharma, API, Ichthyosis, Patient, CVR, LEO, Isotretinoin, FDA, NYSE, Pharmaceutical industry

LEO Pharma today announced that it signed an agreement to acquire U.S.-listed Timber Pharmaceuticals, Inc. (NYSE American: TMBR.

Key Points: 
  • LEO Pharma today announced that it signed an agreement to acquire U.S.-listed Timber Pharmaceuticals, Inc. (NYSE American: TMBR.
  • The deal is subject to certain closing conditions including, but not limited to, Timber Pharmaceuticals’ shareholder approval.
  • Christophe Bourdon, CEO of LEO Pharma commented:
    “Signing an agreement to acquire Timber Pharmaceuticals and TMB-001, which is still subject to certain closing conditions, is an additional step in delivering on our strategy.
  • Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases.

EMA Accepts LEO Pharma’s Marketing Authorization Application (MAA) for Delgocitinib Cream in Chronic Hand Eczema (CHE)

Retrieved on: 
Friday, August 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Janus, Leo Pharma, Marketing, DELTA, JAK, European Medicines Agency, Committee on Herbal Medicinal Products, Inflammation, EMA, Pain, Patient, Standard of care, Delgocitinib, LEO, Itch, MAA, Skin, Safety, CHMP, Pharmaceutical industry

LEO Pharma A/S announces today that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).

Key Points: 
  • LEO Pharma A/S announces today that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).
  • “We are delighted that delgocitinib cream has entered this first stage of the European regulatory process.
  • “Chronic hand eczema negatively impacts patients’ quality of life, psychological well-being, physical functioning, and ability to work.
  • LEO Pharma is currently developing delgocitinib in a cream formulation for the treatment of moderate to severe CHE in adults.

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Retrieved on: 
Friday, August 18, 2023
Well, ICON PLC, Subjectivity, ICON, Incidence, Magnetic resonance imaging, Translational research, Conditional sentence, Digital, Health, Neurology, Clinical, Software, CT, CVS, Infection, HIV disease progression rates, Molecular Probes, Safety, Endocrinology, Leo Pharma, Echocardiography, Biotechnology, Cancer, Radiopharmaceutical, IXICO, Drug, Partnership, Drug development, Clinical trial, PET, We Are One (global collaboration song), Cardiology, Pharmaceutical industry, Medical imaging, Medical device

The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022

Key Points: 
  • The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
    Based on product, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
    Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area.
  • Clinical Trial Imaging Market Dynamics:
    Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    The major players operating in this market are ICON plc.